Infectious Disease Division, Department of Medicine, Uniformed Services University of the Health Sciencesgrid.265436.0, Bethesda, Maryland, USA.
Division of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
mBio. 2021 Aug 31;12(4):e0127421. doi: 10.1128/mBio.01274-21. Epub 2021 Jul 20.
The first step in HIV-1 entry is the attachment of the envelope (Env) trimer to target cell CD4. As such, the CD4-binding site (CD4bs) remains one of the few universally accessible sites for antibodies (Abs). We recently described a method of isolating Abs directly from the circulating plasma and described a panel of broadly neutralizing Abs (bnAbs) from an HIV-1 "elite neutralizer" referred to as patient N49 (N49 Ab lineage [M. M. Sajadi, A. Dashti, Z. R. Tehrani, W. D. Tolbert, et al., Cell 173:1783-1795.e14, 2018, https://doi.org/10.1016/j.cell.2018.03.061]). Here, we describe the molecular details of antigen recognition by N49P6, an Ab of the N49 lineage that recapitulates most of the neutralization breadth and potency of the donor's plasma IgG. Our studies done in the context of monomeric and trimeric antigens indicate that N49P6 combines many characteristics of known CD4bs-specific bnAbs with features that are unique to the N49 Ab lineage to achieve its remarkable neutralization breadth. These include the omission of the CD4 Phe cavity and dependence instead on interactions with highly conserved gp120 inner domain layer 3. Interestingly, when bound to BG505 SOSIP, N49P6 closely mimics the initial contact of host receptor CD4 to the adjacent promoter of the HIV-1 Env trimer to lock the trimer in the closed conformation. Altogether, N49P6 defines a new class of near-pan-neutralizing, plasma deconvoluted CD4bs Abs that we refer to as the N49P series. The details of the mechanisms of action of this new Ab class pave the way for the next generation of HIV-1 bnAbs that can be used as vaccine components of therapeutics. Binding to target cell CD4 is the first crucial step required for HIV-1 infection. Thus, the CD4-binding site (CD4bs) is one of the most accessible sites for antibodies (Abs). However, due to steric constraints, only a few Abs are capable of targeting this site. Here, we show that the exceptional neutralization breadth and potency of N49P6, a near-pan-neutralizing Ab targeting the CD4bs isolated from the plasma of an HIV-1 "elite neutralizer," patient N49, are due to its signature combination of more typical CD4bs Ab-binding characteristics with unique interactions with the highly conserved gp120 inner domain. In addition, we also present a structural analysis of N49P6 in complex with the BG505 SOSIP trimer to show that N49P6 exhibits remarkable breadth in part by mimicking CD4's quaternary interaction with the neighboring gp120 protomer. In its mode of antigen interaction, N49P6 is unique and represents a new class of CD4bs-specific bnAbs.
HIV-1 进入的第一步是包膜 (Env) 三聚体与靶细胞 CD4 的附着。因此,CD4 结合位点 (CD4bs) 仍然是少数几个普遍可用于抗体 (Abs) 的位点之一。我们最近描述了一种从循环血浆中直接分离 Abs 的方法,并从被称为患者 N49 的 HIV-1“精英中和剂”中描述了一组广泛中和的 Abs (bnAbs) (M. M. Sajadi, A. Dashti, Z. R. Tehrani, W. D. Tolbert, et al., Cell 173:1783-1795.e14, 2018, https://doi.org/10.1016/j.cell.2018.03.061)。在这里,我们描述了 N49P6 抗原识别的分子细节,N49P6 是 N49 谱系中的一种 Ab,它再现了供体血浆 IgG 的大部分中和广度和效力。我们在单体和三聚体抗原背景下进行的研究表明,N49P6 将许多已知的 CD4bs 特异性 bnAbs 的特征与 N49 Ab 谱系特有的特征结合起来,从而实现了其显著的中和广度。这些特征包括省略 CD4 苯丙氨酸腔,转而依赖与高度保守的 gp120 内部结构域 3 的相互作用。有趣的是,当与 BG505 SOSIP 结合时,N49P6 紧密模拟了宿主受体 CD4 与 HIV-1 Env 三聚体相邻启动子的初始接触,从而将三聚体锁定在闭合构象中。总之,N49P6 定义了一类新的近泛中和、血浆去卷积 CD4bs Abs,我们称之为 N49P 系列。这种新的 Ab 类的作用机制的细节为下一代 HIV-1 bnAbs 的发展铺平了道路,这些 bnAbs 可以作为治疗性疫苗的组成部分。 与靶细胞 CD4 的结合是 HIV-1 感染所需的第一个关键步骤。因此,CD4 结合位点 (CD4bs) 是抗体 (Abs) 最容易接近的位点之一。然而,由于空间位阻的限制,只有少数 Abs 能够靶向该位点。在这里,我们表明,N49P6 的非凡中和广度和效力,一种针对来自 HIV-1“精英中和剂”患者 N49 的血浆中分离的 CD4bs 的近泛中和 Ab,是由于其独特的组合更典型的 CD4bs Ab 结合特征与高度保守的 gp120 内部结构域的独特相互作用。此外,我们还通过 N49P6 与 BG505 SOSIP 三聚体的结构分析表明,N49P6 部分通过模拟 CD4 与相邻 gp120 原聚体的四级相互作用来实现其显著的广度。在其抗原相互作用模式中,N49P6 是独特的,代表了一类新的 CD4bs 特异性 bnAbs。